On March 3, 2026, the Food and Drug Administration announced that it had sent 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1s. For a brand that sells medication online, an FDA warning letter is now as much a marketing risk as a manufacturing one. FDA described the March letters as the second group of their kind since its September crackdown on direct-to-consumer drug ads.
"It's a new era," FDA Commissioner Marty Makary said in the announcement. The agency, he added, is "paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms." Any brand in weight-loss telehealth, or selling any compounded medication, benefits from knowing how these letters are put together and what the FDA objected to.
What the Letter Is For
A warning letter is how the FDA often notifies a firm of what it believes are significant violations of federal requirements. FDA's page on warning and close-out letters explains that the letter requests a response within a certain timeframe, giving the firm a chance to address FDA's concerns. A firm that disagrees can supply its reasoning and supporting information. Across the campaign that began in September, FDA has described its letters as warnings to pharmaceutical and telehealth firms to remove misleading ads.
The timeframe is set in each letter, so read it there rather than assuming a standard number of days. For a telehealth brand, the more useful point is what the letter contains. It is written to one firm about that firm's own claims, which makes it one of the clearest public records of where FDA draws the line on telehealth marketing.
Reading It Part by Part
For a telehealth brand's marketing team, three parts of the letter matter most.
The Violations
This is where FDA quotes or describes the claims it objects to. Read this part against every place the brand speaks to patients: the website, product pages, ads, emails, social posts, and affiliate or influencer pages. A claim FDA quoted from one page often appears elsewhere in slightly different words, so search for the idea behind the claim as well as the exact phrase. Note where each quoted claim came from, whether the brand's own site, a paid ad, or a partner's post, since each one is corrected through a different channel.
The Response Request
The letter asks for a response within its timeframe. If the firm disagrees with a finding, this is where it supplies its reasoning and supporting information. If it agrees, this is where it shows what it has corrected, and listing the specific pages and posts that changed, with dates, gives FDA something concrete to review.
The Public Copy
FDA posts warning letters on its website, and it may redact or edit them to remove confidential information. The letter isn't private correspondence. Patients, competitors, payment partners, and journalists can all read it, and it names the firm alongside the claims FDA quoted.
What FDA Cited in the 2026 Telehealth Letters
The March announcement described two kinds of claims behind the letters.
Claims of Sameness
FDA cited "claims implying sameness with FDA-approved products." Compounded drugs are not FDA-approved, which means the FDA does not review them for safety, effectiveness, or quality before they reach patients. A medication compounded by a 503A or 503B pharmacy can share an active ingredient with an approved product. Still, the FDA objected to copy that presents it as the approved product or as equivalent to it. Makary stated the agency's view directly: "compounders should not try to compound drugs in a way that circumvents FDA's approval process."
Phrases that compare the product to a brand-name drug, use the approved product's name to sell the compounded one, or call it a generic version deserve a second look.
The Brand Name on the Product
FDA also cited products "branded with the telehealth firm's name or trademark without qualification." A label or product page that shows only the telehealth brand can suggest the brand made the medication, when a pharmacy compounded it. Brands working with a white-label pharmacy face this question directly because the model puts the brand's name on a product someone else makes. The citation focused on advertising for products branded this way, so it applies to product pages, ads, social posts, and the package label. label
Who Compounds the Product on Bask
On Bask, the parts of a compounded product are split between the brand and the pharmacy that makes it:
| Part of the product | Who handles it on Bask |
|---|
| Compounding | A 503A or 503B pharmacy in Bask's network |
| Formulation, dosage, and form | The brand chooses |
| Packaging and labels, including branding, dosage instructions, and patient information | The brand chooses |
| Shipping | The pharmacy ships the finished medication to the patient in all 50 states |
Because brands choose the labels and branding through Bask's compounding service, they also decide how clearly the label and the product page say which pharmacy compounded the medication. FDA's second citation turns on exactly that detail.
The prescription reaches the pharmacy through the platform's e-prescribing tools, written by a clinician from the integrated doctor groups included in every Bask plan. The patient-facing side is where the brand's own words live: the intake questionnaire, and the website, landing pages, and email templates built in Bask's builder. Those words belong to the brand, and a marketing team should check them against the 2026 letters.
Responding and Getting to Close-Out
Start by finding every place the cited claims appear. FDA said it is watching "all media platforms," so the search goes beyond the website to ads, emails, social posts, influencer and affiliate pages, and any landing page built for a campaign. Correct each one and send the response within the letter's timeframe, including any reasoning and supporting information the brand wants the FDA to consider. For each corrected claim, keep a record of:
- Where the claim appeared, with the URL or post
- The original wording
- The corrected wording, or a note that the page or post was removed
- The date of the change
Affiliate and influencer content is the easiest to miss, because the brand didn't write it. When a partner's post repeats a cited claim, ask for the change and add the request to the same record.
LegitScript certification is a separate review with its own standards. Holding it doesn't answer an FDA letter, and answering the letter doesn't replace the certification review.
The FDA handles the final step. FDA may issue a close-out letter once it determines the firm has taken corrective action, usually verified through a follow-up inspection.
FAQs
Is an FDA Warning Letter Public?
Yes. FDA posts warning letters on its website, and some are redacted or edited to remove confidential information.
Does a Warning Letter Mean a Product Is Banned?
A warning letter is notice that FDA found a significant violation, with a request to respond and correct it. What the firm is asked to do is set out in the letter itself.
How Long Does a Firm Have to Respond to an FDA Warning Letter?
The letter sets the timeframe. FDA's page says a warning letter requests a response within a certain timeframe, and it doesn't name a standard number of days, so the date to work from is the one in the letter.
Do Supplement Brands Get FDA Warning Letters?
Yes. Warning letters aren't limited to prescription drugs, and supplement brands can receive them over the claims they make about their products.
References
- U.S. Food and Drug Administration. (2024). About warning and close-out letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters
- U.S. Food and Drug Administration. (2026, March 3). FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
